Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WSD 0922

Next Previous
Drug Profile

WSD 0922

Alternative Names: BBB Penetrable EGFR/EGFRvIII Inhibitor WSD0922-FU; EGFR Mutant Inhibitor WSD0922-FU; WSD-0922; WSD-0922-FU

Latest Information Update: 14 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wayshine Biopharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Astrocytoma; Brain metastases; Glioblastoma

Most Recent Events

  • 14 Oct 2025 Phase I development is ongoing in Brain metastases, Glioblastoma, Non-small-cell-lung-cancer in the US (PO) (NCT04197934)
  • 03 Oct 2025 Wayshine Biopharm plans a phase I/II trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line or greater therapy in China (PO) (NCT07206498)
  • 18 Aug 2025 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in France, China, USA (PO) (NCT06868485)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top